Three European biomedical research infrastructures — EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking) and ELIXIR (focused on data sharing) — are paving the way towards developing and sharing best practices for biomarker validation.
Few biomarkers progress from discovery to become validated tools or diagnostics have been reported lately. A group of renowned biomarker experts, including Martin Smit, from the management team of BiomarkerBay, come together to discuss the reasons for this gap and highlight some potential solutions based on developing and sharing best practices through greater collaboration.
"An updated long-term vision for Europe is necessary. It requires structural use of the relevant permanent infrastructures, tasked with ensuring standards and quality of the resources to which they provide access, and sharing of knowledge, to ensure robustness of the project outcomes and to reduce uncertainty along the biomarker pipeline. Close collaboration of the major stakeholders in the biomarker community is necessary to defragment the pipeline and ensure efficient capture of good practices"
Close collaboration will allow not only to define and share good biomarker practice guidelines but also to support researchers for efficient execution of translational biomarker projects.
The full publication can be found here.
